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SUMMARY
Flaviviruses cause systemic or neurotropic-encephalitic pathology in humans. The flavivirus 
nonstructural protein 1 (NS1) is a secreted glycoprotein involved in viral replication, immune 
evasion, and vascular leakage during dengue virus infection. However, the contribution of secreted 
NS1 from related flaviviruses to viral pathogenesis remains unknown. Here, we demonstrate that 
NS1 from dengue, Zika, West Nile, Japanese encephalitis, and yellow fever viruses selectively 
binds to and alters permeability of human endothelial cells from lung, dermis, umbilical vein, 
brain, and liver in vitro and causes tissue-specific vascular leakage in mice, reflecting the 
pathophysiology of each flavivirus. Mechanistically, each flavivirus NS1 leads to differential 
disruption of endothelial glycocalyx components, resulting in endothelial hyperpermeability. Our 
findings reveal the capacity of a secreted viral protein to modulate endothelial barrier function in a 
tissue-specific manner both in vitro and in vivo, potentially influencing virus dissemination and 
pathogenesis and providing targets for antiviral therapies and vaccine development.
In Brief
Puerta-Guardo et al. discover that five flavivirus NS1 proteins trigger hyperpermeability and 
vascular dysfunction in human endothelial cells and mice in a manner reflecting disease tropism. 
This tissue-specific tropism is partially determined by the capacity of NS1 to bind endothelial cells 
and is characterized by disruption of endothelial glycocalyx components.
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Graphical Abstract
INTRODUCTION
The Flavivirus genus consists of enveloped, positive-sense RNA viruses (~11-kb genome) 
that are transmitted by arthropod vectors, collectively causing hundreds of millions of 
infections each year. Flaviviruses include medically important mosquito-borne pathogens 
such as the four dengue virus serotypes (DENV1-DENV4), Zika virus (ZIKV), West Nile 
virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV) (Calisher 
and Gould, 2003). In humans, flavivirus infections result in a range of outcomes, from 
clinically inapparent infections to severe, sometimes fatal disease, characterized by 
hemorrhagic manifestations and vascular leakage with organ failure (DENV and YFV), 
meningomyeloencephalitis (JEVand WNV), and congenital Zika syndrome in pregnant 
women and Guillain-Barré syndrome in adults associated with ZIKV infection (Gould and 
Solomon, 2008; Krauer et al., 2017).
The flavivirus genome encodes three structural proteins (C, prM/M, and E) and seven 
nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). NS1 is a 
multifunctional viral protein that is secreted as a hexamer by infected cells and circulates in 
the host bloodstream (Muller and Young, 2013). Inside infected cells, NS1 acts as a cofactor 
for viral replication and assembly, while the secreted form plays a role in immune evasion 
by binding and triggering degradation of the complement protein C4 (Avirutnan et al., 2010; 
Mackenzie et al., 1996; Scaturro et al., 2015) and in dengue pathogenesis via activation of 
complement (Avirutnan et al., 2006). Additionally, NS1 has been shown to contribute to 
dengue pathogenesis by directly triggering endothelial hyperpermeability as well as by 
Puerta-Guardo et al. Page 2
Cell Rep. Author manuscript; available in PMC 2019 December 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
inducing the release of vasoactive cytokines from peripheral blood mononuclear cells 
(PBMCs) via activation of TLR4, both leading to vascular leak (Beatty et al., 2015; 
Modhiran et al., 2015). Further, DENV NS1 has been shown to directly alter the barrier 
function of pulmonary endothelial cell monolayers through disruption of the endothelial 
glycocalyx-like layer (EGL) by triggering the activation of endothelial sialidases, cathepsin 
L, and heparanase, enzymes responsible for degrading sialic acid and heparan sulfate 
proteoglycans (Puerta-Guardo et al., 2016). Importantly, disruption of endothelial 
glycocalyx components has been shown to correlate with plasma leakage during severe 
DENV infection (Suwarto et al., 2017; Tang et al., 2017). More recently, the contribution of 
these DENV NS1-induced endothelial cell-intrinsic pathways to NS1-mediated vascular 
leakage was demonstrated to be independent of inflammatory cytokines but dependent on 
the integrity of endothelial glycocalyx components both in vitro and in vivo (Glasner et al., 
2017).
NS1 is well conserved among flaviviruses, exhibiting 20%–40% identity and 60%–80% 
similarity (Song et al., 2016; Xu et al., 2016). During the acute phase of illness in patients 
with severe dengue disease, DENV NS1 has been shown to circulate at high levels (1–2 μg/
mL), correlating with DENV viremia (Libraty et al., 2002). Human studies describing the 
kinetics of circulating NS1 levels in other flavivirus infections are lacking, although NS1 has 
been detected in the serum of mice experimentally infected with ZIKV, WNV, JEV, and 
YFV (Chung and Diamond, 2008; Liu et al., 2016, 2017; Macdonald et al., 2005). Notably, 
ZIKV NS1 has been found in placental tissues infected with ZIKV (Jurado et al., 2016). 
This suggests that, in addition to the effect of NS1 circulating in serum on the luminal side 
of endothelial cells lining blood vessels, the action of NS1 in relation to vascular leak may 
also occur in capillary beds of tissues, where the cumulative effect of NS1 is likely amplified 
and/or concentrated.
Here, we demonstrate that NS1 proteins from dengue, Zika, West Nile, Japanese 
encephalitis, and yellow fever viruses selectively alter the permeability of monolayers of 
endothelial cell lines derived from distinct human tissues. Additionally, we find that 
flavivirus NS1 proteins differentially induce disruption of EGL components, critical 
determinants of endothelial barrier function (Reitsma et al., 2007). Further, NS1 proteins 
enhance the extravasation of fluids in vivo in a tissue-dependent manner, which correlates 
with flavivirus pathophysiology. Together, our findings reveal a previously unidentified 
ability of flavivirus NS1 proteins to modulate endothelial permeability in a tissue-specific 
manner both in vitro and in vivo, potentially influencing flavivirus dissemination, 
pathogenesis, and disease.
RESULTS
Flavivirus NS1 Proteins Trigger Endothelial Barrier Dysfunction in a Tissue-Specific 
Manner
Previously, we demonstrated that NS1 proteins from all four DENV serotypes, but not the 
related WNV, cause a dose-dependent increase in endothelial permeability of human 
pulmonary microvascular endothelial cells (HPMECs) (Beatty et al., 2015; Puerta-Guardo et 
al., 2016). Further, we showed that DENV2 NS1 alone is able to induce vascular leakage in 
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vivo (Beatty et al., 2015; Glasner et al., 2017). Here, we used a trans-endothelial electrical 
resistance (TEER) assay to evaluate the ability of DENV, ZIKV, WNV, JEV, and YFV NS1 
proteins to trigger endothelial barrier dysfunction in distinct human endothelial cell 
monolayers, including pulmonary (HPMECs), dermal (human microvascular dermal 
endothelial cells [HMEC-1]), umbilical vein (human umbilical vein endothelial cells 
[HUVECs]), brain (human brain microvascular endothelial cells [HBMECs]), and liver 
(human liver sinusoidal microvascular endothelial cells [HLSECs]). Recombinant flavivirus 
NS1 proteins used in all experiments were produced in mammalian cells (HEK293) and 
were shown to be >95% pure and oligomeric, as demonstrated by native PAGE followed by 
silver staining or western blot analyses (Figure S1A). NS1 protein concentrations used in 
these experiments were based on levels of NS1 circulating in patients with severe dengue 
disease and on previous studies demonstrating the effect of DENV NS1 on human 
endothelial cells (Beatty et al., 2015; Glasner et al., 2017; Puerta-Guardo et al., 2016). 
Interestingly, our results show that the different NS1 proteins trigger hyperpermeability in 
endothelial cells derived from tissues associated with the viral tropism of each flaviviral 
disease (Figures 1 and S1B-S1F). Specifically, NS1 from DENV, which causes systemic 
disease, induces endothelial hyperpermeability in all endothelial cells tested, while NS1 
from ZIKV, which targets the placenta and developing brain, induces hyperpermeability only 
in umbilical vein and brain endothelial cells. NS1 from both Uganda and Suriname strains 
behaved similarly (Figures S2A and S2B). NS1 from WNV and JEV, which cause 
encephalitis, induce hyperpermeability only in brain endothelial cells, whereas NS1 from 
YFV, which is systemic but primarily causes hepatic damage, exerted the strongest effect in 
liver endothelial cells, with a slight increase of permeability in lung endothelial cells. All 
endothelial cells demonstrated increased permeability when exposed to the pro-
inflammatory cytokine tumor necrosis factor alpha (TNF-α) as a positive control. However, 
no increase in permeability was observed with recombinant DENV2 E protein, 
demonstrating that the hyperpermeability induced is an NS1-specific effect (Figure 1). The 
TEER results were confirmed in a solute flux assay using 70-kDa dextran conjugated to 
fluorescein isothiocyanate (FITC) as a tracer in HUVEC monolayers (Figure S2C).
In addition to our endothelial permeability assays, we assessed the ability of each flavivirus 
NS1 protein to interact with the surface of the different human endothelial cells in vitro by 
performing NS1 binding assays. Briefly, NS1 proteins were added to confluent monolayers 
of human endothelial cells, and the amount of NS1 bound to the surface of the endothelial 
cell monolayers was determined by immunofluorescence microscopy. At 1 h post-treatment 
(hpt), all NS1 proteins showed a binding pattern that reflected their capacity to selectively 
induce endothelial hyperpermeability as measured by TEER (Figures 2A–2E and S3A). 
DENV NS1 bound in a dose-dependent manner to the surface of all endothelial cells, 
showing maximum binding to pulmonary endothelial cells. ZIKV NS1 showed highest 
binding to umbilical vein endothelial cells and brain endothelial cells. WNV NS1 and JEV 
NS1 only exhibited increased binding capacity to brain endothelial cells. Surprisingly, YFV 
NS1 bound to all endothelial cells; however, significantly higher amounts were found on 
liver endothelial cells (Figures 2 and S3). These binding patterns were confirmed by western 
blot analysis of cell lysates from confluent monolayers of human endothelial cells exposed 
to individual flavivirus NS1 proteins (Figures 2F–2J and S3B-S3F).
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Further, the specificity of the interactions of NS1 with the surface of human endothelial cells 
was corroborated by testing the effect of an anti-6x-His-tag monoclonal antibody (mAb) 
targeting the tag on the NS1 proteins and an NS1-specific mAb on DENV-NS1-induced 
barrier dysfunction of HPMECs, as measured by TEER (Figure S3G), and on NS1’s 
interaction with HPMEC and 293F cells, as measured by immunofluorescence microscopy 
and flow cytometry, respectively (Figures S3H and S3I). As expected, the anti-His-tag mAb 
did not prevent either the DENV-NS1-induced hyperpermeability of HPMECs or NS1 
binding to HPMECs and 293F cells. However, the anti-NS1 mAb blocked the barrier 
dysfunction induced by NS1 in HPMECs as well as NS1 binding to HPMECs and 293F 
cells. These results indicate that the different flavivirus NS1 proteins have the ability to bind 
to distinct tissue-specific endothelial cells, potentially leading to the endothelial dysfunction 
and hyperpermeability identified in the TEER assay (Figure 1).
To identify a specific region of the flaviviral NS1 protein necessary for the distinct 
endothelial cell binding patterns observed (Figure 2), we constructed a chimeric mutant 
comprised of a DENV NS1 backbone containing amino acids 101–135 from WNV NS1 
(DENVWNV101–135). We had previously identified this region of DENV NS1, known as the 
wing domain, as immunodominant in mice and humans (Hertz et al., 2017), and another 
study implicated this region as critical for antibody-mediated inhibition of NS1-induced 
pathogenesis in humans (Lai et al., 2017). We hypothesized that if this region of the wing 
domain contributed to the differential ability of DENV and WNV NS1 to bind to HPMECs, 
then this chimeric mutant would behave like WNV and display diminished binding to 
HPMECs. Using our 293-protein expression system, we produced and isolated this chimeric 
mutant. As expected, when we compared the ability of DENV, WNV, and DENVWNV101–135 
NS1 proteins to bind to HPMECs, we observed that DENVWNV101–135 NS1 bound 
significantly less than DENV NS1, binding comparably to WNV NS1 (Figures S4A and 
S4B). These data suggest that the wing domain of NS1, particularly the motif between 
amino acids 101 and 135, is critical for the differential NS1 binding patterns observed on 
HPMECs.
Intriguingly, the differential binding patterns of the NS1 proteins (Figure 2) correlated with 
the capacity to trigger endothelial hyperpermeability (Figure 1) for all NS1 proteins except 
YFV NS1. This suggests that binding to endothelial cells is not sufficient for NS1 to trigger 
endothelial hyperpermeability. Because DENV NS1 was previously shown to be internalized 
by hepatocytes (Alcon-LePoder et al., 2005), we hypothesized that YFV NS1 bound to but 
was not internalized by all endothelial cell lines. To test this hypothesis, we compared 
internalization of DENV and YFV NS1 into HBMECs (where DENV, but not YFV NS1, 
triggered hyperpermeability) and HLSECs (where both NS1 proteins induced 
hyperpermeability), as determined by colocalization of NS1 with the early endosome marker 
Rab5. We found that while DENV NS1 was efficiently internalized into both cell types, 
YFV NS1 was only significantly internalized into HLSECs (Figures S4C and S4D). This 
selective internalization of YFV NS1 suggests that both binding and internalization are 
required for NS1 to trigger endothelial hyperpermeability.
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Flavivirus NS1 Proteins Induce Degradation of EGL Components after Triggering Sialidase 
and Cathepsin L-Heparanase Activation in Human Endothelial Cells In Vitro
The EGL is a network of glycosaminoglycans (GAGs) and membrane-bound proteoglycans 
and glycoproteins expressed on the endothelium that lines the luminal surface of blood 
vessels and contributes to barrier function critical for vascular homeostasis (Weinbaum et al., 
2007). Previously, we demonstrated that DENV NS1, but not WNV NS1, activates 
endothelial cell-intrinsic pathways that lead to barrier dysfunction of HPMECs in vitro. NS1 
triggered loss of sialic acid from the cell surface upon activation of endothelial sialidases as 
well as the shedding of heparan sulfate proteoglycans by activating endothelial cathepsin L 
and heparanase (Puerta-Guardo et al., 2016). To establish whether different flavivirus NS1 
proteins induce endothelial cell-specific barrier dysfunction via activation of similar 
mechanisms, polarized monolayers of HPMECs, HMEC-1, HUVECs, HBMECs, and 
HLSECs were exposed to the different flavivirus NS1 proteins. The integrity of EGL 
components was evaluated 6 hpt using immunofluorescence staining for sialic acid (Figures 
3 and S5A), heparan sulfate (Figures 4 and S5B), and syndecan-1, a major heparan-sulfate-
bearing proteoglycan that supports the integrity of the EGL (Choi et al., 2011) (Figures S6A 
and S6B). DENV NS1 induced disruption of sialic acid on all endothelial cells, with 
significant reductions in sialic acid expression that ranged from 20% to 80% depending on 
the endothelial cell type. Reflecting the pattern observed in endothelial permeability (Figure 
1), ZIKV NS1 disrupted sialic acid in both HUVECs and HBMECs, whereas WNV NS1 and 
JEV NS1 only disrupted sialic acid on HBMECs. A significant reduction in expression of 
sialic acid on HLSECs was only observed in response to YFV NS1 (Figure 3). Regarding 
expression of heparan sulfate and syndecan-1, degradation of heparan sulfate after treatment 
with the distinct flavivirus NS1 proteins was detected on the surface of the different human 
endothelial cells after 6 hpt following a pattern that reflected our observations for sialic acid 
expression (Figure 4). Of note, treatment of endothelial cells with recombinant envelope 
protein of DENV did not change the surface levels of these EGL components (Figures S5A 
and S5B). In parallel, accumulation of syndecan-1, whose ectodomain binds back to the 
surface of endothelial cells after being shed (Choi et al., 2011), was detected on the surface 
of the different endothelial cells 6 hpt in a similar pattern (Figures S6A and S6B). Thus, 
disruption of EGL components was also determined by the flavivirus NS1 protein and the 
tissue-specific endothelial cell.
We also evaluated the effect of flavivirus NS1 proteins on activity and expression of 
endothelial cathepsin L and expression of the endoglycosidase heparanase, enzymes 
involved in the degradation of EGL components (Glasner et al., 2017; Puerta-Guardo et al., 
2016). Compared to untreated monolayers, DENV NS1 increased the expression and activity 
of cathepsin L in all endothelial cells (Figures 5A, 5B, S5C, S6C, and S6D). ZIKV NS1 
increased levels of cathepsin L expression and proteolytic activity in cultures of umbilical 
vein endothelial cells and brain endothelial cells. NS1 proteins from DENV, ZIKV, WNV, 
and JEV, but not YFV, modulated expression levels of cathepsin L and increased its activity 
in brain endothelial cells. Finally, YFV NS1 stimulated the proteolytic activity of cathepsin 
L in liver endothelial cells to levels 25-fold higher than untreated controls, whereas ZIKV 
NS1, WNV NS1, and JEV NS1 triggered no response (Figures 5A, 5B, S5C, S6C, and 
S6D). We also examined the maturation state of cathepsin L on different endothelial cells 
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exposed to distinct NS1 proteins at 6 hpt. Densitometry analyses of western blots revealed 
expression of the pro-cathepsin L form in all endothelial cells exposed to different NS1 
treatments but increased appearance of the active form of cathepsin L (Figures 5C–5E) that 
reflected the results obtained using the fluorescence proteolytic activity assay (Figures 5A, 
5B, and S6D) and correlated with the patterns of hyperpermeability observed in Figure 1. As 
before, the activation of cathepsin L was specific to NS1, as the DENV E protein failed to 
significantly trigger maturation of cathepsin L (Figure S5C). Because proteolytic activity of 
cathepsin L is required for the activation of heparanase and subsequent trimming of heparan 
sulfate from the EGL (Abboud-Jarrous et al., 2008), we also examined the expression of 
heparanase in endothelial cells after NS1 stimulation using immunofluorescence 
microscopy. As before, we observed a similar cell-type- and NS1-dependent pattern of 
heparanase expression compared to the cathepsin L results (Figures 5F and S6C).
Additionally, expression of endothelial sialidases (Neu1, Neu2, and Neu3), glycosidases that 
catalyze the removal of terminal sialic acids of glycoproteins and glycolipids, was evaluated 
on endothelial cells treated with the different flavivirus NS1 proteins (Figures S7A-S7D). 
Compared to untreated cells, flavivirus NS1 proteins led to increased expression of Neu1, 
Neu2, and Neu3 in a cell-type-dependent manner at 6 hpt. In the case of DENV NS1, which 
increased the permeability of all the evaluated endothelial cells, Neu2 was the most 
upregulated sialidase in all endothelial cells, followed by Neu3 and Neu1. ZIKV NS1 
upregulated the expression of Neu2 and Neu3 in HUVECs. Regarding the encephalitic 
flaviviruses, only HBMECs showed significant changes in the expression of the three 
sialidases in response to WNV and JEV NS1. Finally, for YFV NS1, which significantly 
increased the permeability of liver endothelial cells, the expression of Neu2 and Neu3 was 
significantly upregulated only in HLSECs, with some increase in Neu2 in HPMECs, also 
consistent with the patterns observed above.
Flavivirus NS1 Proteins Cause Increased Vascular Leakage in a Tissue-Dependent Manner 
and Induce Disruption of Endothelial Glycocalyx Components In Vivo
We next examined the ability of NS1 proteins from different flaviviruses to cause localized 
dermal or systemic vascular leakage in vivo using murine models. To evaluate dermal leak, 
we performed a fluorescent dextran-adapted Miles assay as previously described 
(Glasneretal., 2017). Briefly, following intradermal injection of recombinant NS1 proteins, 
fluorescently labeled (Alexa Fluor 680) dextran was delivered intravenously, and 2 h later, 
leakage in the dorsal dermis was visualized using a fluorescence detection system. We found 
that DENV NS1, but not ZIKV, WNV, JEV, or YFV NS1, induced a significant increase in 
vascular leakage in the murine dermis compared to injection of PBS (Figures 6A and 6B). 
To characterize the systemic effects of flavivirus NS1, we used a traditional Miles assay to 
evaluate induction of vascular leak in organs, including the brain, lungs, and liver. Mice were 
inoculated with 10 mg/kg flavivirus NS1, an amount that leads to circulating levels of NS1 
equivalent to human dengue hemorrhagic fever (DHF)-dengue shock syndrome (DSS) cases 
(Beatty et al., 2015; Libraty et al., 2002). Three days post-inoculation (dpi), animals were 
administered Evans blue dye or Alexa-Fluor-680-labeled dextran for subsequent tissue 
extraction or fluorescent imaging, respectively. Following inoculation of DENV NS1, 
increased amounts of Evans blue dye were detected in the lungs and liver (Figures 6C and 
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6D). However, consistent with previous studies (Beatty et al., 2015), no significant 
extravasation of Evans blue dye was observed after inoculation of 10 mg/kg ovalbumin 
(OVA). YFV NS1 was the only other NS1 protein to induce significantly higher levels of 
Evans blue dye leakage in the liver (Figure 6D).
We also examined vascular leak in the brain and lung by measuring the accumulation of 
fluorescently labeled dextran. We used fluorescently labeled dextran instead of Evans blue 
dye to measure vascular leak in the brain, because this reagent showed greater sensitivity in 
our assay compared to Evans blue dye. Further, because both WNV and JEV are neurotropic 
flaviviruses, we only included WNV in subsequent mouse experiments to minimize the 
number of mice per experiment. Intravenous administration of DENV, ZIKV, or WNV NS1 
proteins resulted in significant accumulation and extensive leakage of dextran in brain tissue 
compared to OVA and YFV NS1 treatments (Figure 6E–6G). In the lungs, accumulation of 
dextran following inoculation with DENV NS1 resembled the extravasation pattern observed 
with Evans blue dye in the Miles assay, with large areas of increased mean fluorescence 
intensity (MFI) that result from the accumulation of dextran in tissue (Figures 6F–6H). In 
contrast, administration of WNV NS1 and OVA (used as a protein control) resulted in no 
dextran accumulation (Figures 6F–6H). Using this assay, mice inoculated with YFV and 
ZIKV NS1 proteins showed areas of leakage in the lung with increased MFI for dextran 
compared to OVA but substantially less than DENV NS1, suggesting a minimal level of 
vascular leak from the inoculation (Figures 6F–6H). Depending on their molecular size, 
dextran molecules can be used to test solute and ion permeability (low-molecular-weight 
dextran), indicating paracellular pathways. Therefore, leakage in the lung induced by YFV 
NS1 may be preferentially measured by smaller solute tracers, suggesting a potential 
increased paracellular transport of solutes between endothelial cells. Finally, to evaluate the 
impact of flavivirus NS1 proteins on vascular leakage in vivo, we investigated the effect of 
intravenous administration of NS1 proteins on the circulation of heparan sulfate, a major 
GAG used as an indirect marker of endothelial glycocalyx integrity in vivo. For this assay, to 
minimize numbers of mice per experiment, we included one systemic flavivirus (DENV), 
one encephalitic virus (WNV), and one hepatotropic virus (YFV). Compared to untreated 
mice and mice treated with OVA (used as a protein control), administration of DENV, YFV, 
and, to a lesser extent, WNV NS1 proteins led to increased serum levels of heparan sulfate 
(DENV, p = 0.0002; YFV, p = 0.0233; WNV, p = 0.0231) (Figure 6I), suggesting that 
shedding of heparan sulfate may indeed be a consequence of activation of the cathepsin L-
heparanase pathway by NS1.
DISCUSSION
In this study, we describe the capacity of NS1 proteins from DENV, ZIKV, WNV, JEV, and 
YFV to induce hyperpermeability of cultured polarized human endothelial cells derived 
from different tissues, including lung, skin, umbilical vein, brain, and liver, as measured by 
TEER. These findings are supported by in vivo data collected using both Evans blue dye and 
fluorescently labeled dextran, showing that flavivirus NS1 proteins can differentially and 
selectively induce vascular leakage in distinct organs, including lung, skin, brain, and liver, 
reflecting respective flaviviral pathophysiology. We found that DENV NS1 induced 
hyperpermeability in all tested human endothelial cells, with maximal effects observed on 
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pulmonary endothelial cells. DENV NS1 also stimulated vascular leak in all evaluated 
organs upon inoculation into mice. ZIKV NS1 increased the permeability of umbilical vein 
and brain endothelial cells in vitro and caused vascular leakage in the brain in vivo, whereas 
WNV NS1 and JEV NS1 only induced hyperpermeability of brain endothelial cells and 
substantial vascular leakage in the mouse brain. NS1 from YFV significantly increased the 
permeability of endothelial cells derived from liver and, to a lesser extent, lung, and this 
same pattern was seen in murine organs in vivo. Mechanistically, the observed 
hyperpermeability in vitro is related to disruption of the EGL components sialic acid, 
heparan sulfate, and syndecan-1 following upregulation of sialidases as well as cathepsin L 
expression and activity and subsequent expression of heparanase, enzymes known to 
contribute to the degradation of cellular GAGs and proteoglycans in the EGL. Taken 
together, our results indicate that flavivirus NS1 proteins modulate endothelial permeability 
in a tissue-specific manner both in vitro and in vivo, potentially influencing flavivirus 
dissemination, pathogenesis, and disease (Figure 7).
Clinically, severe WNV and JEV infections, as well as fetal ZIKV infections during 
pregnancy, primarily result in cerebrovascular disease with encephalitis or congenital brain 
abnormalities with neurological complications (Gould and Solomon, 2008; Krauer et al., 
2017). In contrast, severe DENV and YFV infections are generally associated with systemic 
disease, characterized primarily by increased vasculopathy and plasma leakage from blood 
vessels into tissues, as well as hepatic damage/dysfunction (World Health Organization, 
2009). However, there are multiple reports describing DENV-associated neurological 
complications such as encephalitis and DENV infection in the human brain in autopsies, as 
well as detection of viral antigens in placental tissues from DENV-infected mothers (Balsitis 
et al., 2009; Kumar et al., 2008; Ribeiro et al., 2017; Soni et al., 2017). These findings 
indicate that DENV may also breach the blood-brain barrier as well as reach the placenta 
during pregnancy. Overall, our data here demonstrate a tissue-specific pattern of interaction 
between flavivirus NS1 and endothelial cells, where NS1-mediated effects mirror the clinical 
pathophysiology of the corresponding flaviviral disease in humans. Data are lacking 
regarding levels of flavivirus NS1 in humans (other than DENV), especially in tissues, 
where vascular leak occurs. Regardless of levels of circulating NS1 antigenemia, the 
cumulative effect of NS1 is likely amplified and/or concentrated in the capillary beds of 
tissues, the primary sites of leakage.
Vascular leak is apparently mediated by the specific interaction and subsequent 
internalization of NS1 proteins in different endothelial cells. Our data showed that DENV 
NS1 binds to the surface of all human endothelial cells we studied but displayed a greater 
interaction with lung and liver endothelial cells, correlating with the pathophysiology of 
severe DENV disease (i.e., pleural effusion and liver dysfunction) (World Health 
Organization, 2009). ZIKV NS1 was found only on the surface of umbilical vein and brain 
endothelial cells. Interestingly, ZIKV infects fetal macrophages (Hofbauer cells) and 
placental villous fibroblasts, resulting in increased expression and secretion of ZIKV NS1 in 
placenta villus cores where fetal endothelial cells are present in blood vessels (Jurado et al., 
2016; Tabata et al., 2016). Additionally, ZIKV infects human PBMCs in vivo and neural 
progenitor cells in vitro, suggesting that ZIKV NS1 may circulate in the blood of infected 
patients and be secreted in brain tissues (Michlmayr et al., 2017; Mlakar et al., 2016; Tang et 
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al., 2016). WNV NS1 and JEV NS1 only interacted with brain endothelial cells, which 
correlated with their ability to induce hyperpermeability of these human endothelial cells as 
well as with their well-described neurotropism, resulting in neurological complications and 
encephalitis (Diamond and Klein, 2004). NS1 from YFV, most often associated with severe 
liver disease and systemic organ failure (Monath and Barrett, 2003), was unexpectedly found 
to bind to some degree to all human endothelial cells. However, it bound to liver endothelial 
cells to the highest level, which was the only cell type that displayed a high degree of YFV-
NS1-induced hyperpermeability. This suggests that binding of NS1 to endothelial cells is not 
sufficient to explain NS1-triggered vascular leak and that further downstream steps, such as 
internalization, may further dictate this tissue-specific tropism. This concept is supported by 
our data showing that YFV NS1 can bind to but is not significantly internalized by 
HBMECs, whereas it binds to and is internalized by HLSECs. This indicates that 
internalization of NS1 may well be important for NS1-triggered endothelial 
hyperpermeability. These results further suggest that NS1 binding specificity may rely on 
the tissue-specific expression of surface molecules on different endothelial cells that may 
facilitate the early stages of NS1 binding via protein-protein or protein-glycan interactions. 
Preliminary studies to investigate the specificity of NS1 binding and its role in endothelial 
cell- type- and tissue-specific hyperpermeability suggest a very complicated interplay 
between certain EGL-associated cellular attachment factors, such as GAGs and 
proteoglycans, and the different flavivirus NS1 proteins, modulated by the level of sulfation 
and complexity of glycan moieties in the EGL as well as particular motifs on the NS1 
proteins. With regard to the molecular determinants of DENV NS1 required to bind to 
endothelial cells, results obtained using the chimeric mutant DENVWNV101–135 NS1 
implicates a particular region of the wing domain of NS1 as crucial for endothelial cell 
binding and ultimately endothelial hyperpermeability. Further characterization of this and 
other regions of NS1 is critical to decipher the biochemical mechanism behind NS1 binding 
from the viral side and is the focus of additional studies. From the host side, the cognate 
NS1 attachment factor(s) and receptors) remain elusive, and their identification requires 
numerous additional experiments in the fields of glycobiology, proteomics, and molecular 
genetics.
The vascular endothelium is composed of a single layer of endothelial cells that form blood 
vessels and modulate vascular homeostasis. The negative charge provided by EGL 
components, including glycoproteins containing sialic acid residues and GAGs, such as 
heparan sulfate (more than 50% of the total GAG pool), chondroitin sulfate, and hyaluronic 
acid, contribute to the maintenance of endothelial barrier function (Weinbaum et al., 2007). 
Degradation of the EGL has been linked to disease severity in several viral hemorrhagic 
fever diseases (Connolly-Andersen et al., 2014), including dengue, where increased levels of 
heparan sulfate, hyaluronic acid, and syndecan-1 have been found in the blood of patients 
with severe dengue disease as compared to controls with milder forms of dengue (Suwarto et 
al., 2017; Tang et al., 2017; Trung and Wills, 2010). However, the importance of vascular 
permeability and the role of EGL components in the pathogenesis of other flavivirus 
infections is still unknown. Here, we found that NS1-induced endothelial hyperpermeability 
correlates with increased disruption of key EGL components, regardless of the tissue origin 
of the human endothelial cells. The interaction of distinct flavivirus NS1 proteins with the 
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surface of different human endothelial cells led to significantly decreased expression of 
sialic acid and heparan sulfate, suggesting degradation of these components. This interaction 
also resulted in increased deposition and accumulation of syndecan-1, which, after being 
shed, can bind back to the endothelial surface, inducing endothelial dysfunction (Choi et al., 
2011; Puerta-Guardo et al., 2016). Importantly, inoculation of these recombinant NS1 
proteins in a mouse model, particularly DENV, YFV, and WNV, led to a systemic increase in 
the levels of heparan sulfate, confirming the role of NS1 in remodeling the integrity of EGL 
components in endothelial beds in vivo and is consistent with increased heparan sulfate 
circulation in severe human dengue cases with vascular leak (Tang et al., 2017). Notably, 
NS1-induced EGL alterations in vitro were associated with increased expression and 
activation of endothelial sialidases (Neu1, Neu2, and Neu3), the cysteine protease cathepsin 
L, and the endoglycosidase heparanase, which have been implicated in the degradation of 
the extracellular matrix as well as cleavage of proteoglycans mainly expressed on the 
luminal surface of endothelial cells (Abboud-Jarrous et al., 2008; Choi et al., 2011; 
Weinbaum et al., 2007). The pattern revealed is consistent with the flavivirus NS1- and 
tissue-specific profiles reported above. However, the molecular mechanisms leading to 
upregulation and activation of the mammalian sialidases are still unknown. In turn, cathepsin 
L is known to activate heparanase after proteolytic processing of the non-active precursor 
into an active protein. We previously showed that inhibitors of sialidases, heparanase, and 
cathepsin L prevent NS1-induced disruption of the EGL in vitro and vascular leak in vivo 
(Glasner et al., 2017; Puerta-Guardo et al., 2016). Thus, we found that the cell-type-
dependent pattern of endothelial hyperpermeability observed following flavivirus NS1 
treatment of human cell monolayers is also reflected in endothelial cell-intrinsic mechanisms 
implicated in NS1 pathogenesis in vitro and putative disruption of the endothelial glycocalyx 
in a mouse model.
The assessment of vascular permeability is complicated, because it is affected by multiple 
factors, including the type of microvessels, endothelial cells, the size and charge of 
extravasating molecules, and the pathway that molecules take to traverse the endothelium. In 
addition to the glycocalyx layer, the hemostasis of the endothelium is maintained by the 
presence of intercellular junctional complex composed of protein-protein interactions that 
help to preserve the cell-to-cell contacts (Dejana, 2004). In these studies, we utilized five 
distinct measures of endothelial permeability and vascular leak: TEER and a dextran flux 
assay in vitro, Evans blue dye and fluorescently labeled dextran in a systemic Miles assay in 
vivo, and fluorescently labeled dextran in a modified local Miles assay in vivo. These assays 
all assess endothelial permeability, but because of the nature of the assays, they potentially 
measure different pathways. In vitro, TEER measures the ohmic resistance of a barrier, 
whereas flux assays measure the direct passage of a macromolecule from the apical to the 
basolateral chamber. Both of these methods represent a composite of both paracellular and 
transcellular pathways. In vivo, Evans blue binds to albumin, which does not cross the 
endothelium in the absence of inflammation or stimulus that disrupts normal barrier 
function. On the other hand, 10-kDa dextran should extravasate from the blood into tissue 
even during basal conditions (Egawa et al., 2013). As with the in vitro models, these assays 
most likely measure a composite of paracellular and transcellular pathways. The results from 
each of these models support our overarching hypothesis that NS1 exerts a virus- and tissue-
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specific effect on the human endothelium, leading to barrier dysfunction and 
hyperpermeability, but the amount of leakage due to transcellular versus paracellular 
pathways remains unknown, and further studies are needed to elucidate the molecular 
mechanisms driving this phenomenon. As the primary determinant of paracellular 
permeability, intercellular junctions are important regulators of endothelial barrier function, 
though it is likely that both the glycocalyx and intercellular junctions are involved in NS1-
induced barrier dysfunction and that multiple factors work in synergy, resulting in 
endothelial hyperpermeability (Chen et al., 2016; Glasner et al., 2018). Discerning the 
relative contributions of the glycocalyx and intercellular junctions will undoubtedly prove to 
be challenging, but a more complete understanding of the dynamics and kinetics involved in 
disruption of the endothelial barrier by NS1 may inform clinical management and treatment 
protocols for flavivirus disease.
Flavivirus infection has been shown to compromise the integrity of many biological barriers, 
including the pulmonary microvascular endothelium and the blood-brain barrier, which are 
usually able to protect against virus infection (Li et al., 2015; Puerta-Guardo et al., 2013; 
Spindler and Hsu, 2012; Wang et al., 2004). So far, this process has been primarily attributed 
to exacerbated host immune responses that lead to increased permeability of endothelial 
cells in the different microvascular beds. However, the role of secreted flaviviral factors such 
as NS1 proteins in the pathophysiology of endothelial cells has not been reported, other than 
DENV NS1. Despite the mounting evidence showing that high levels of NS1 antigenemia 
during the acute phase of DENV infection correlate with increased risk of developing severe 
dengue disease, including vascular leakage (Song et al., 2016), little is known about 
circulating levels of NS1 from other flavivirus infections, including ZIKV, WNV, JEV, and 
YFV. Here, our data suggest a potential role for flavivirus NS1 proteins in causing tissue-
specific pathology associated with endothelial dysfunction. We hypothesize that NS1 may 
induce selective hyperpermeability of different microvascular beds as a means of facilitating 
virus dissemination into target organs where permissive cells critical for local replication are 
found, resulting in virus amplification. Numerous studies of flavivirus infection in different 
animal models as well as human autopsies have shown a selective tropism of distinct groups 
of flaviviruses that target different tissues, leading to systemic versus neurotropic-
encephalitic pathology (Gould and Solomon, 2008; Muller and Young, 2013). Despite 
studies describing the potential infection of endothelial cells by flaviviruses in vitro, 
flavivirus infection of endothelial cells in vivo is still controversial. In this study, infection of 
endothelial cells by DENV and ZIKV does not occur during the time frame of the 
experiment (12–24 h) (data not shown). Thus, we posit that NS1 is a virulence factor that, in 
addition to facilitating virus replication and immune evasion, may also facilitate virus 
dissemination from the bloodstream into tissues, influencing virus tissue tropism and disease 
manifestations.
Taken together, we report a previously undescribed function of different flavivirus NS1 
proteins in modulating endothelial barrier function in vitro and in vivo in a tissue-dependent 
manner. Mechanistically, we found that all NS1 proteins were able to alter the integrity of 
EGL components on the surface of endothelial cells, leading to endothelial 
hyperpermeability. This evidence strongly suggests that distinct flavivirus NS1 proteins may 
modulate virus dissemination and thus influence viral pathogenesis and disease. These 
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findings provide insight into the biology of NS1 and contribute to a better understanding of 
flavivirus pathogenesis, supporting the inclusion of NS1 protein in flavivirus vaccine 
development and generating new targets for future therapies against flavivirus infections.
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Eva Harris (eharris@berkeley.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cultured human endothelial cells—Human pulmonary microvascular ECs (HPMEC) 
(line HPMEC-ST1.6R) were kindly donated by Dr. J.C. Kirkpatrick at Johannes Gutenberg 
University, Germany. HPMEC were isolated from adult male human donors, and the 
immortalized-selected clone (HPMEC-ST1.6R) displayed all major constitutively expressed 
and inducible phenotypic markers for endothelial cells. Human umbilical vein ECs 
(HUVEC) were a kind gift from Melissa Lodoen at the University of California, Irvine. 
HUVEC are primary endothelial cells obtained from a single female donor (Lonza). Both 
cell lines, HPMEC and HUVEC, were propagated (passages 5–10) and maintained in 
endothelial cell basal medium-2 supplemented with growth factors: FBS (5%), 
hydrocortisone (0.2 ml), R3-IGF-1 (0.5 ml), Ascorbic Acid (0.5 ml), hEGF (2 ml), and 
gentamicin-1000 (0.5 ml) as per the manufacturer’s specifications (Lonza). The human 
dermal microvascular endothelial cell line HMEC-1 (isolated from a newborn male), kindly 
donated by Dr. Matthew Welch, University of California, Berkeley, was propagated 
(passages 18–25) and maintained using MCDB 131 medium (Sigma) supplemented with 1% 
penicillin/streptomycin (Life Technologies), 0.2% Epidermal Growth Factor (Life 
Technologies), 0.4% hydrocortisone (Sigma), and 5% Fetal Bovine Serum (Corning). The 
human brain microvascular endothelial cells (HBMEC) were donated by Ana Rodriguez at 
New York University. HBMEC were obtained from ScienCell Research Laboratories 
(gender not available) and maintained at low passages (passages 8–10) using endothelial cell 
medium supplemented with FBS (5%), 5 mL of endothelial cell growth supplement (ECGS, 
Cat. No. 1052), and 5 mL of penicillin/streptomycin (ScienCell Research Labs). The 
primary human liver sinusoidal microvascular endothelial cells (HLSEC) were acquired 
from Cell Biologics (adult male donor) and maintained using complete human EC medium 
and EC medium supplement kit according to the manufacturer’s recommendations. All 
human endothelial cells were tested to be mycoplasma free, kept at low passage at 37° C in 
humidified air with 5% CO2, and routinely passaged prior to reaching 100% confluence. 
FreeStyle 293F suspension cells (Thermo Fisher Scientific) used to produce in house 
recombinant NS1 protein and to examine the binding of NS1 by flow cytometry were both 
cultured in FreeStyle 293 Expression medium (Thermo Fisher Scientific) supplemented with 
1% penicillin/streptomycin and maintained inside a humid chamber at 37°C and 8% CO2 at 
a density of 0.15–1.2×106 cells/ml on a cell shaker at 135 rpm. 293 cells are human-female 
embryonic kidney epithelial cells.
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Mice—Five- to eight-week old wild-type C57BL/6 male mice were purchased from the 
Jackson Laboratory (Sacramento, CA) and maintained under specific pathogen-free 
conditions at the University of California, Berkeley, Animal Facility. Mice were housed in a 
controlled temperature environment on a 12-hour light/dark cycle, with food and water 
provided ad libitum. All experimental procedures involving animals were pre-approved by 
the Animal Care and Use Committee (ACUC) of the University of California, Berkeley.
METHOD DETAILS
Production and purification of recombinant proteins—Recombinant NS1 proteins 
from DENV2 (Thailand/16681/84), ZIKV (Uganda MR766 and Suriname Z1106033), 
WNV (NY99), JEV (SA-14), and YFV (17D) were commercially acquired from The Native 
Antigen Company (Oxfordshire, United Kingdom). These proteins were produced in 
HEK293 cells with a purity greater than 95%, composed mostly of oligomeric forms as 
confirmed by silver staining and western blot assays (Figure S1) and certified by the 
manufacturer to be free of endotoxin contaminants. The recombinant DENV2/WNV 
chimera (aa101–135WNV), was generated in house using FreeStyle 293F suspension cells 
(Thermo Fisher Scientific) and the primers: 1r: CTC TTT CCC CAG GCC TTC CAG CCA 
ATT TCC AAT TTT TCC GTG GTG GCG GTG AGG CGT TTA GGT CCT GCC TGC 
ATG ATT CCT TTG ATG and 2f: TGG AAG GCC TGG GGA AAG AGT ATT TTA TTT 
GCA CCA GAA CTC GCC AAC AAC ACC TTT GTG GTT GAT GGC CCC GAA ACA 
GCA GAA. Transfections of 293F cells were performed using FreeStyle MAX transfection 
reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol, and 
supernatant containing NS1 was collected 48 hours post-transfection. The 6x-His-tagged 
recombinant DENV NS1 proteins were purified by batch method using nickel nitrilotriacetic 
acid resin agarose beads (Thermo Fisher Scientific). Recombinant E protein from DENV2 
[recE80% (aa 1–3970)] was kindly donated by Dr. Aravinda M. de Silva at the University of 
North Carolina, Chapel Hill. RecE was expressed and purified from supernatants of Sf21 
cells infected with a baculovirus system. All recombinant protein preparations were 
confirmed to be endotoxin-free (< 0.001) using the Endpoint Chromogenic Limulus 
Amebocyte Lysate QCL-1000TM kit (Lonza).
Trans-endothelial electrical resistance (TEER) to measure endothelial 
permeability—The effect of recombinant flavivirus NS1 proteins on endothelial 
permeability was evaluated by measuring TEER of endothelial cell (EC) monolayers grown 
on a 24-well Transwell polycarbonate membrane system (Transwell® permeable support, 
0.4 μm, 6.5 mm insert; Corning Inc.). Briefly, human endothelial cells (80%–90% 
confluency) cultured in vented-75 cm2 flasks (Corning®) were detached using a 
combination of three washing steps using sterile 1X PBS supplemented with EDTA (2 mM) 
(lifting buffer), followed by two additional washing steps (~30 s total) using a solution of 
trypsin-EDTA (0.25%) (GIBCO®, Thermo Scientific). Detached cells were resuspended 
using fresh culture media and then counted using a tissue-culture hemocytometer. A total of 
60,000 cells for HPMEC, HMEC-1, HUVEC, and HBMEC or 80,000 cells (HLSEC) were 
seeded in the apical side of Transwell inserts (top chamber), using a final volume of 300 μL 
per well (top chamber). Each Transwell was transferred inside a 24-well format plate 
containing 1.5 mL of endothelial cell culture media, which represents the basolateral side of 
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each Transwell. Transwells containing endothelial cells were incubated at 37°C and 5% CO2 
for 3 days, and 50% of culture medium was changed in each well 48 hours post-seeding. 
Cells were grown until TEER values between 150 and 180 Ohms (Ω) were reached, 
depending on cell type, indicating 100% cell confluency. After this, a single dose of 
recombinant protein including different flavivirus NS1 proteins (5 and 10 μg/ml, 1.5 and 3 
μg total protein, respectively), recE (5 μg/ml, 1.5 μg total protein), and TNF-α (10 ng/ml, 3 
ng total protein), were added to the apical side of the Transwell insert (top chamber, 300 μl) 
containing the cell monolayer. TEER values, expressed in Ohms (Ω), were collected at 
sequential 2-hour time-points following the addition of test proteins using an Epithelial Volt 
Ohm Meter (EVOM) with “chopstick” electrodes (World Precision Instruments). 
Endothelial permeability was expressed as relative TEER which represents a ratio of 
resistance values (Ω) as follows: (Ω experimental condition - Ω medium alone)/(Ω non-
treated endothelial cells - Ω medium alone). After 24 hours of treatment, 50% of upper and 
lower chamber media was replaced by fresh endothelial cell medium. Then, TEER was 
measured 3 hours (27 hpt) and 24 hours later (48 hpt).
Solute flux assay—To evaluate the effect of different flavivirus NS1 proteins on the 
passage of macromolecules through a polarized monolayer of human ECs, HUVEC (60,000 
cells/Transwell insert) were grown on collagen-coated Transwell inserts (Corning Transwell-
COL collagen-coated membrane inserts, 24-well, 0.4 μm, 6.5 mm insert; Corning Inc.). 
After three days of culture using complete endothelial cell media (Lonza), 50% of upper and 
lower chamber media was replaced with fresh EC Growth Media-2 (PromoCell) for 24 hours 
before beginning the experiment. Test proteins (10 μg/ml, 3 μg total protein) were added to 
the apical chamber of the Transwell inserts and incubated for 6 hours at 37°C. At 6 hpt, 70-
kDa dextran conjugated to FITC (Sigma) was added to the apical chamber of the Transwell 
inserts at a final concentration of 1 mg/ml and allowed to circulate for one hour at 37°C. 
Transwell inserts were removed, and 100 μL from each well was collected from duplicate 
wells and transferred to a 96-well flat-bottom plate. Fluorescence was measured on a plate 
reader, and the concentration of dextran-FITC that passed from the apical to the basolateral 
chamber was determined using a standard curve (0.488 – 1000 μg/ml). TNF-α (100 ng/ml, 
30 ng total protein) was used as a positive control, and untreated cell monolayers were used 
as a baseline control.
Flavivirus NS1 protein binding assay—To assess the ability of each flavivirus NS1 
protein to interact with the surface of human endothelial cells, we used two different 
approaches: an immunofluorescence assay (IFA) to visualize the extracellular NS1 protein 
(5 and 10 μg/ml; 1.5 and 3 μg total protein, respectively) on non-permeabilized monolayers 
of endothelial cells grown on 0.2% gelatin-coated coverslips (Sigma); and a western blot 
assay using total protein extracts collected from confluent endothelial cell monolayers 
exposed to 10 μg/ml (3 μg) of each NS1 protein. For both assays, individual flavivirus NS1 
proteins were incubated for one hour at 37°C and 5% CO2 in a total volume of 300 μl. All 
flavivirus NS1 proteins used in this study contain a C-terminal 6x-His-tag. NS1 protein 
bound to the cell surface was detected using an anti-6x-His-tag mAb (HIS.H8) conjugated to 
Alexa Fluor 647 (Thermo Scientific) followed by confocal microscopy analyses. Briefly, 
after one-hour post-treatment with NS1 proteins, the anti-6x-His-tag mAb conjugated to 
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Alexa Fluor 647 was added into the same culture media at a dilution of 1:200 and incubated 
for 30 minutes protected from light. Both unbound NS1 and anti-His antibody were 
removed, and cell monolayers were washed twice with washing buffer (1X PBS + 2% FBS) 
before being fixed with 4% formaldehyde (Thermo Scientific) diluted in washing buffer. 
Untreated cells were used as a negative background control for non-specific anti-His 
antibody binding to the surface of endothelial cells. Hoechst 33342 (0.125 μl/slide) was used 
to stain the nuclei. ImageJ was used to estimate the amount of NS1 bound to the cell surface 
after image processing and analysis, expressed as mean fluorescence intensity values (MFI). 
Additionally, the binding ability of DENV NS1 (5 μg/ml) was tested on 293F cells in the 
presence and absence of the anti-6x-His-tag antibody (10 μg/ml) measured by flow 
cytometry using an anti-NS1 mAb in house-conjugated to Alexa Fluor 568. DENV NS1 
binding was estimated from the positive signal obtained from non-NS1 treated cells, used as 
a negative control for NS1-treated cells equally stained with the Alex Fluor 568-conjugated 
anti-NS1 mAb. Flow cytometry data analyses of NS1 positive cells was performed by 
FlowJo V10.
Alternatively, a combination of anti-6x-His-tag mAb with an anti-mouse IgG (H+L) 
conjugated to Alexa Fluor 680 was used to detect the presence of NS1 protein in total 
protein extracts by western blot using an infrared detection system (LI-COR). Briefly, pre-
chilled culture plates (15 minutes at 4°C) containing confluent monolayers of human 
endothelial cells (4–5 days in culture) were treated with a single dose of distinct flavivirus 
NS1 proteins (10 μg/ml). Culture plates were then immediately transferred to 4°C for 
additional 45 minutes of incubation. Later, plates were transferred to 37°C for 1.5 hours. 
Monolayers were then washed twice with cold 1X PBS followed by two subsequent 
treatments with a solution of pre-warmed trypsin-EDTA(0.25%) (GIBCO®, Thermo 
Scientific) until cells rounded. At this point, the trypsin solution was aspirated away gently, 
and monolayers were detached using cold 1X PBS + 2% FBS. Cells were transferred into 
low protein binding microcentrifuge tubes (0.6 ml, Fisher Scientific) and pelleted by 
centrifugation at 4°C at 1,500 rpm for 5 minutes. The cell pellet was rinsed twice with cold 
sterile 1X PBS. The supernatant was carefully discarded after every wash step. Cell pellets 
were resuspended in 50 mL of cold 1X PBS, transferred into a new tube containing ~500 μl 
of 1X PBS, and centrifuged at 1,500 rpm at 4°C for 5 minutes. Supernatant was discarded, 
and cell lysis was performed by directly adding 60 μLof Laemmli sample buffer (60 
mMTris-Cl pH 6.8,2% SDS, 10% glycerol, 100 mM DTT, and 0.01% bromophenol blue) to 
the cell pellet. Equal volumes of cell lysates (30 μl/well) were loaded and separated under 
reducing conditions using SDS-PAGE polyacrylamide gradient gel (4%–20% Criterion TGX 
Precast Midi Protein Gel, BioRad), and running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS) at a constant voltage of 100 V for 1.5 hours. Blotting was performed using Trans-Blot 
Turbo Mini PVDF Transfer Packs (Cat# 1704156, BioRad) and Trans-Blot Turbo Transfer 
System (BioRad). PVDF membranes were blocked using a mix of skimmed milk (5%) and 
bovine serum albumin (BSA, 1%) diluted in TBS-T (Tris-buffered saline 20mM pH 7.4; 
NaCl 150 mM, and 0.1% Tween-20) for 45 minutes at room temperature and gentle 
oscillation. The amount of NS1 bound to the cell surface was measured using an anti-6x-
His-tag primary antibody (1:500 diluted in TBS-T overnight at 4°C), followed by an anti-
mouse IgG conjugated to Alexa Fluor 750 used as the secondary antibody (1:5000 diluted in 
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TBS). NS1 was detected after infrared detection analyses using LICOR imaging software. 
GAPDH was used as a protein loading control to normalize the relative amount of NS1 
protein bound to the surface of each endothelial cell. An anti-rabbit IgG conjugated to Alexa 
Fluor 680 was used as a secondary antibody for GAPDH. Untreated monolayers were used 
as a negative control for background subtraction. Densitometry analyses was performed 
using Image Studio Lite software v 5.2 (LI-COR Biosciences).
Flavivirus NS1 internalization assay—To examine the internalization of recombinant 
NS1 proteins from DENV and YFV by human endothelial cells, pre-chilled monolayers of 
HBMEC and HLSEC grown in 300 μL of cell culture media on coverslips pre-coated with 
0.2% gelatin (Sigma) were exposed to 10 μg/ml of individual NS1 proteins (3 mg total 
protein) and incubated for 45 minutes at 4°C. Plates were then transferred to 37°C and 
incubated for 1.5 hours to facilitate NS1 protein internalization into endothelial cells. 
Inoculum was removed and monolayers were rinsed twice with 1X PBS + 2% FBS. Cells 
were then fixed for 20 minutes in 4% formaldehyde diluted in 1X PBS + 2% FBS and then 
for 20 minutes in 1 mL of cold 100% methanol added on top of the formaldehyde, followed 
by a 20-minute permeabilization/blocking step in 1X PBS + 0.2% saponin + 2% FBS + 1% 
BSA. Internalization of NS1 was demonstrated by co-staining NS1 (6x-His-tag mAb; 1:50 
in 1X PBS) and an early endosome marker, Rab5 (1:50 in 1X PBS), using 
immunofluorescence microscopy. Both primary antibodies were incubated overnight at 4°C. 
Anti-mouse IgG Alexa Fluor 568 and anti-rabbit IgG Alexa Fluor 488 (1:100 dilution in 1X 
PBS) were used as secondary antibodies, incubated for 2 hours at room temperature with 
light protection. Hoechst 33342 (0.125 μl/slide) was used to stain the nuclei. For staining, 
coverslips were incubated on parafilm containing ~15 μl/slide of the primary or secondary 
antibody diluted in 1X PBS with the cell side of the coverslip facing down onto the antibody 
containing drop inside a humid chamber. Coverslips were rinsed 4 times with 1X PBS 
between antibody probing steps. Coverslips were mounted on glass slides onto a drop of 
ProLong® Gold Antifade Mountant (Thermos Scientific, Cat# P36934). ImageJ was used 
for image processing and analyses. Quantification of colocalization between NS1 and Rab5 
was determined by manually counting NS1-positive cells and evaluating them for 
colocalization with Rab5 puncta. At least 50 NS1-positive events were quantified for two 
individual experiments.
Fluorescence microscopy and analysis of EGL components on endothelial 
cells—For imaging experiments, all human endothelial cells were grown on sterile 
coverslips coated with 0.2% gelatin (Sigma) and imaged on a Zeiss LSM 710 Axio Observer 
inverted fluorescence microscope equipped with a 34-channel spectral detector (CRL 
Molecular Imaging Center, UC Berkeley). To visualize the effect of all flavivirus NS1 
proteins on the expression of EGL components such as sialic acid, heparan sulfate, and 
syndecan-1, as well as expression of endothelial sialidases (Neu1, Neu2, and Neu3), 
cathepsin L expression and activity, and heparanase expression, confluent endothelial cell 
monolayers were treated with 5 μg/ml of each flavivirus NS1 protein. After 6 hpt, cell 
monolayers were rinsed twice with 1X PBS + 2% FBS before fixing with cold 4% 
formaldehyde (FA) diluted in the same buffer. Untreated monolayers were used as a control 
for normal expression/distribution of all EGL components and endothelial enzymes 
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mentioned above. For staining sialic acid, wheat germ agglutinin (WGA) conjugated to 
Alexa Fluor 647 (5 μg/ml) was incubated with live cells (300 μl) for 30 minutes at 37°C and 
5% CO2. Next, coverslips were rinsed twice with 1X PBS + 2% FBS and fixed with 4% 
formaldehyde diluted in the same buffer for 20–30 minutes at 4°C, light protected. To stain 
heparan sulfate, after fixing the monolayers with 4% formaldehyde, coverslips were 
incubated overnight at 4°C with an anti-heparan sulfate antibody (1:50 in 1X PBS). Then, an 
anti-mouse IgM Alexa Fluor 488 (1:100 in 1X PBS) was used as secondary. For other EGL 
markers, cells were fixed for 20 minutes in 4% formaldehyde diluted in 1X PBS + 2% FBS 
and then for 20 minutes in 1 mL of cold 100% methanol added on top of the formaldehyde, 
followed by a 20-minute permeabilization/blocking step in 1X PBS + 0.2% saponin + 2% 
FBS + 1% BSA. After this, primary antibodies against Neu1, Neu2, and Neu3 (1:50); 
syndecan-1 (1:50), human heparanase (1:25), and cathepsin L (1:50) were incubated 
overnight at 4°C in 1XPBS. Detection of primary mAbs was performed with secondary 
antibody species-specific IgG antibodies conjugated to Alexa fluorophores (568 and 647). 
Coverslips were processed as described above, incubating primary and secondary antibodies 
on top of parafilm sheets inside humid chambers. Hoechst 33342 (0.125 μl/slide) was used 
to stain the nuclei. ProLong® Gold Antifade was used as mounting medium. Images were 
acquired at 20X magnification using Zeiss Zen 2010 software and were processed and 
analyzed with ImageJ software. All RGB images were converted to grayscale. Then, mean 
grayscale values and integrated density from selected areas were taken, along with adjacent 
background readings, and plotted as mean fluorescence intensity (MFI). For MFI 
quantification, individual images (708.48 × 708.48 μm) were obtained as RGB composites 
and split into 4-channels to adjust the threshold for each individual channel. Then, each 
channel was converted into a grayscale format and equally divided into four framed non-
overlapping areas (341.9 × 353.8 mm, ~45–50 nuclei/frame). MFI was measured using an 
ImageJ plugin. All different experimental conditions were run in duplicate in two individual 
experiments. Representative images (125.73 × 138.96 μm).
Western blots for Cathepsin L expression/activity and Magic Red assay—
Confluent cell monolayers (~300,000 cells/24-well plate, 4–5 days) of human endothelial 
cells from lung (HPMEC), skin (HMEC-1), umbilical vein (HUVEC), brain (HBMEC), and 
liver (HLSEC) were treated with 5 μg/ml of individual flavivirus NS1 proteins (DENV, 
ZIKV, WNV, JEV, and YFV). After 6 hpt, cells were rinsed with cold 1X PBS (three times), 
then monolayers were lysed using Laemmli sample buffer (60 μl/well; 60 mM Tris-Cl pH 
6.8, 2% SDS, 10% glycerol, 100 mM DTT, and 0.01% bromophenol blue). Cell lysates (30 
μl/well) was separated by 4%−20% gradient SDS-PAGE (4%−20% Criterion TGX Precast 
Midi Protein Gel, BioRad) using running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) 
at a constant voltage of 100 V for 1.5 hours. For subsequent analyses, proteins were 
transferred onto PDVF membranes using a Trans-Blot® Turbo Transfer System (BioRad). 
Then, membranes were blocked in TBS-T with skimmed milk (5%) and bovine serum 
albumin (BSA, 1%), 45 minutes at room temperature. Primary anti-human cathepsin L 
antibody (1:50) and anti-GAPDH (1:1000) (used as a housekeeping protein control) were 
incubated overnight at 4°C using fresh blocking buffer in a humid chamber. Secondary anti-
mouse IgG Alexa Fluor 750 and anti-rabbit Alexa Fluor 680 (1:5000 diluted in TBS) were 
used to detect the expression of these two proteins by Odyssey CLx Infrared Imaging 
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System (LI-COR). Densitometry analyses was performed using Image Studio Lite software 
v 5.2 (LI-COR Biosciences). Potential activation of cathepsin L determined by western blot 
was initially identified by the presence of pro-mature Cathepsin L (higher band) versus 
mature-cathepsin L (lower band). The ratio of the densitometry values obtained from each 
experimental condition after normalization with its own loading control (GAPDH) and the 
subtracted background was used to estimate the levels of cathepsin L activation between the 
different NS1 treatments on the distinct endothelial cells compare to those values obtained 
from untreated cells used as basal levels for cathepsin L activation, expressed as fold 
changes.
In addition to this, the activity of cathepsin L in living cells was monitored using the Magic 
Red Cathepsin L detection kit (Immunochemistry Technologies, Inc.). Briefly, confluent 
monolayers of different human endothelial cells (4–5 days of culture) grown on coverslips 
pre-treated with 0.2% gelatin were exposed to flavivirus NS1 proteins (5 μg/ml), and at 6 
hpt, a cell membrane-permeant fluorogenic substrate MR-(Phe-Arg)2 (1:250 dilution per 
well in 300 μl), which contains the cresyl violet fluorophore branded as Magic Red™, was 
added to each well. After 1 hour of incubation at 37°C and 5% CO2 while protected from 
light, cell monolayers were rinsed twice with cold 1X PBS + 2% FBS and then fixed with 
4% formaldehyde diluted in the same buffer. After 30 minutes of incubation at 4°C under 
light protection, all coverslips were rinsed with 1X PBS and then mounted onto glass 
microscope slides containing ProLong® Gold Antifade used as mounting medium. Hoechst 
33342 (0.125 μl/slide) was used to stain the nuclei. Images were acquired at 20X 
magnification using Zeiss LSM 710 AxioObserver and Zeiss Zen 2010 software, then 
processed and analyzed with ImageJ software. Cultured cell monolayers expressing active 
cathepsin L catalyze the hydrolysis of the two Phe-Arg (FRFR) target sequences, generating 
a red fluorescent species that can be detected by immunofluorescence microscopy. Magic 
Red excites at 540–590 nm (590 nm optimal) and emits at > 610nm (630 nm optimal). 
Levels of cathepsin L activation obtained by detection of mean fluorescence intensity (MFI) 
of the whole cell population exposed to different NS1 proteins were expressed as fold 
changes over untreated cells used as control for basal levels of cathepsin L activity.
In vivo vascular leakage assays—To evaluate the in vivo effect of flavivirus NS1 
proteins on vascular hemostasis, we used a conventional Miles assay using Evans blue dye 
(EBD), as well as a modified version using fluorescently-labeled dextran. Briefly, wild-type 
C57BL/6 mice were initially intravenously injected with either 10 mg/kg of ovalbumin or 
each individual flavivirus NS1 protein (10 mg/kg). Three days post-injection, mice were 
intravenously administrated with 100 μl of 0.5% EBD in PBS and 200 μl of 10-kDa dextran 
conjugated to Alexa Fluor 680 (dextran-A680; 1 mg/ml). Both compounds were allowed to 
circulate for 3 or 2 hours, respectively, before euthanizing animals and perfusing tissues with 
20 mL of PBS and 10 mL of formalin solution (Sigma) for tissue fixation. To quantify the 
levels of vascular leakage into the extravascular space of tissue using dextran-A680, tissues 
were harvested and transferred into a 6-well format tissue culture plate, and the levels of 
infrared signal present in different tissues including brain and lungs were measured using the 
LI-COR Odyssey CLx Imaging System. Brain tissues were manually dissected using a 
disposable scalpel to separate the right and left hemispheres through the longitudinal fissure, 
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and each hemisphere was transferred into a 24-well plate and read on a LI-COR Odyssey 
CLx Imaging System. Images were acquired using Image Studio Lite software, and the 
leakage area was quantified from a standard-scanned area selected for each tissue to obtain a 
Mean Fluorescence Intensity value using ImageJ analyses. Representative images were 
selected after ImageJ processing and analyses showing the leakage area in brain and lungs in 
red compare to the autofluorescence signal (in blue) emitted by biological tissues. All RGB 
images were converted to grayscale. Then, mean grayscale values and integrated density 
from selected areas were taken, along with adjacent background readings, and plotted as 
leakage area, mean fluorescence intensity (MFI).
For EBD extraction, in order to remove the excess water/fixative buffer accumulated during 
perfusion and tissue harvesting, each tissue was initially chopped into small pieces, 
transferred into an Eppendorf tube (1.5 ml), then vacuum dried, snap-frozen in liquid 
nitrogen, and pre-weighed before incubation in formamide (1 ml/g of tissue; Sigma) at 65°C 
for 72 hours. Formamide is a chemical commonly used to extract extravasated, fixed, 
accumulated-EBD in tissues. Then, supernatant containing extracted EBD from tissue was 
collected after centrifugation at 10,000–12,000 rpm and transferred to a clean tube. The 
absorbance of the extravasated dye was measured at 620 nm using a spectrophotometer. 
EBD concentration was calculated using a standard curve (3.9 to 250 ng/ml in formamide) 
and linear regression analysis (R2 = 0.998). To determine the effect of flavivirus NS1 
proteins at a local microvascular level, we used the Dextran-adapted dermal Miles assay. 
Briefly, flavivirus NS1 proteins were intradermally injected (15 μg in 50 μl PBS) into the 
Nair-depilated dorsal dermis of mice (hair removed 3–4 days prior to injection). PBS (50 ml) 
was used as an injection control, and VEGF (200 ng in 50 μl PBS) was used as positive 
control for inducing vascular leakage. Following intradermal injections, 200 μl of Alexa 
Fluor 680-conjugated 10-kDa dextran (5 mg/ml) was delivered by retro-orbital injection. 
Two hours post-injection, mice were euthanized, and the dorsal dermis was carefully 
removed and placed in a Petri dish. Tissues were then scanned using the LI-COR Odyssey 
CLx Imaging System, and images were analyzed using Image Studio Lite software to 
quantify the leakage area from a standard-scanned area selected for each site of injection to 
obtain Mean Fluorescence Intensity values.
QUANTIFICATION AND STATISTICAL ANALYSES
Statistical analysis—All statistical analyses and graphs were performed and generated 
using GraphPad Prism 6 software. For microscopy analyses, a comparison between the mean 
fluorescence intensities obtained from three individual experiments, run in duplicate and 
using untreated cells as baseline controls, was conducted using an ordinary two-way analysis 
of variance (ANOVA). Comparison between two groups were carried out using t tests (non-
parametric). Differences were considered significant for p values < 0.05. For vascular 
leakage experiments, a comparison between all groups was conducted using an unpaired, 
nonparametric Mann-Whitney test, and differences in treatment were considered significant 
for p values < 0.05. For in vivo murine dermis experiments, an ordinary one-way ANOVA 
with multiple comparisons to the PBS group using Dunnett’s multiple comparison tests was 
used to determine significance of flavivirus NS1 protein treatments. For TEER experiments, 
statistical significance was determined using a two-way ANOVA, and differences in 
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treatment were considered significant for p values < 0.05. For mean fluorescence intensities 
obtained in immunofluorescence assays, ordinary one-way ANOVA and unpaired non-
parametric tests were used to evaluate the statistically significant differences between all 
groups and individual groups, respectively. Statistically significant differences among means 
were considered as p values < 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Flavivirus NS1 proteins induce endothelial dysfunction in a tissue-specific 
manner
• Tissue tropism of 5 NS1 proteins is partly determined by endothelial cell 
binding
• NS1-induced endothelial dysfunction is mediated by endothelial glycocalyx 
disruption
• Flavivirus NS1 proteins induce tissue-specific leak in mice mirroring viral 
tropism
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Figure 1. Flavivirus NS1 Proteins Trigger Endothelial Barrier Dysfunction In Vitro in a Tissue-
Specific Manner
(A-E) Human endothelial cells from different tissues (A, lung; B, skin; C, umbilical vein; D, 
brain; and E, liver) were grown on Transwell semi-permeable membranes (0.4 μm pore 
size), and distinct flavivirus NS1 proteins (5 μg/mL, 1.5 μg total protein) were added to the 
apical chamber. TNF-α (10 ng/mL) was used as a positive control, and DENV2 
recombinant envelope (E) protein (5 μg/mL) was used as a negative control. A TEER assay 
was used to evaluate the effect of these NS1 proteins on endothelial permeability at indicated 
time-points over 48 h.^ represents media change. Relative TEER values from two 
independent experiments performed in duplicate are plotted. Error bars indicate SEM. 
Statistically significant differences between distinct groups (all time points combined for 
each group) compared to the untreated groups were determined by a two-way ANOVA 
analysis using Dunnett’s test for multiple comparisons, with ****p < 0.0001 and ns (not 
significant), p > 0.05.
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Figure 2. Flavivirus NS1 Proteins Bind Differentially to the Surface of Distinct Human 
Endothelial Cells
Binding of flavivirus NS1 proteins to the surface of different human endothelial cell 
monolayers as measured by (A-E) confocal microscopy or (F-J) western blot. (A-E) (A) 
HPMECs, (B) HMEC-1, (C) HUVECs, (D) HBMECs, and (E) HLSECs were grown on 
coverslips and treated with 5 μg/mL NS1 or10 μg/mL NS1 (1.5 μg or 3 μg of total protein, 
respectively) as indicated (also see Figure S3); binding was evaluated 1 h post-treatment 
(hpt). The amount of bound NS1 was quantified and expressed as MFI.
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(F-J) Cell lysates from (F) HPMECs, (G) HMEC-1, (H) HUVECs, (I) HBMECs, and (J) 
HLSECs treated with 10 μg/mL (3 μg total protein) of flavivirus NS1 protein and collected 1 
hpt and analyzed by western blot (Figure S3). All graphs show the average of quantification 
from two independent experiments run in duplicate. Error bars indicate SEM.
In (A)-(E), statistically significant differences between distinct treatment groups compared 
to the untreated group [NS1(−)] were determined by a two-way ANOVA analysis using 
Dunnett’s test for multiple comparisons, with *p < 0.05, **p < 0.01, ***p < 0.001, and 
****p < 0.0001.
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Figure 3. Flavivirus NS1 Proteins Alter the Expression of Sialic Acid on the Surface of 
Endothelial Cells in a Cell-Type-Dependent Manner
(A) Sialic acid expression on human endothelial cell monolayers grown on coverslips 6 hpt 
with different flavivirus NS1 proteins (5 μg/mL, 1–5 μg total protein), examined by confocal 
microscopy. Sialic acid was stained with wheat germ agglutinin conjugated to Alexa Fluor 
647 (red). Nuclei were stained with Hoechst (blue). Images (20×) are representative of three 
independent experiments. Scale bar, 10 μm.
(B) Quantification of MFI in (A) from three independent experiments. Error bars indicate 
SEM. Reduction of sialic acid expression in NS1-treated monolayers was normalized to 
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untreated controls (dotted line). Statistically significant differences between distinct 
treatment groups compared to the untreated group were determined by a two-way ANOVA 
analysis using Dunnett’s test for multiple comparisons, with *p < 0.05, ***p < 0.001, and 
****p < 0.0001.
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Figure 4. Flavivirus NS1 Proteins Alter the Expression of Heparan Sulfate on the Surface of 
Endothelial Cells in a Cell-Type-Dependent Manner
(A) Heparan sulfate expression on human endothelial cell monolayers grown on coverslips 6 
hpt with different flavivirus NS1 proteins (5 μg/mL, 1–5 μg total protein), examined by 
confocal microscopy. Heparan sulfate was stained with anti-heparan sulfate mAb (green). 
Nuclei were stained with Hoechst (blue). Images (20×) are representative of three 
independent experiments. Scale bar, 10 μm.
(B) Quantification of MFI in (A) from three independent experiments. Error bars indicate 
SEM. Reduction of heparan sulfate expression in NS1-treated monolayers was normalized 
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against untreated controls (dotted line). Statistically significant differences between distinct 
treatment groups compared to the untreated group were determined by a two-way ANOVA 
analysis using Dunnett’s test for multiple comparisons, with *p < 0.05, **p < 0.01, ***p < 
0.001, and ****p < 0.0001.
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Figure 5. Flavivirus NS1 Proteins Modulate the Expression and Activity of Endothelial 
Cathepsin L and Heparanase in a Cell-Type-Dependent Manner
(A and B) Fold change over untreated controls (dotted lines) of the quantification of MFI 
from three independent confocal microscopy experiments examining (A) expression and (B) 
activity of cathepsin L (Magic Red reagent) in human endothelial cell monolayers 6 hpt with 
different flavivirus NS1 proteins (5 μg/mL, 1–5 μg total protein) (Figure S6).
(C) Western blot data of pro- and mature- cathepsin L expression in human endothelial cell 
monolayers 6 hpt with different flavivirus NS1 proteins (5 μg/mL, 1.5 μg total protein).
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(D and E) Densitometry of bands from (C) for (D) pro-cathepsin L and (E) mature cathepsin 
L with values normalized to GAPDH and expressed as fold change from untreated 
monolayers.
(F) Fold change over untreated controls (dotted line) of the quantification of MFI from three 
independent confocal microscopy experiments examining the expression of heparanase in 
human endothelial cell monolayers 6 hpt with different flavivirus NS1 proteins (5 μg/mL, 
1.5 μg total protein) (Figure S6).
For all graphs, error bars indicate SEM. Statistically significant differences between distinct 
treatment groups compared to the untreated group were determined by a two-way ANOVA 
analysis using Dunnett’s test for multiple comparisons, with *p < 0.05, **p < 0.01, ***p < 
0.001, and ****p < 0.0001.
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Figure 6. Flavivirus NS1 Proteins Induce Differential Local and Systemic Vascular Leakage In 
Vivo
(A-H) Wild-type C57BL/6 mice were used to evaluate (A and B) local or (C-H) systemic 
vascular leakage induced by flavivirus NS1 proteins injected either (A and B) intradermally 
(dorsal dermis) or (C-H) intravenously with 15 μg and 200 μg (10 mg/kg) of total protein, 
respectively. The magnitude of the vascular leakage induced by these proteins was evaluated 
by using (A, B, and E-H) Alexa-Fluor-680-conjugated dextran (10 mg/mL) or (C and D) 
Evans blue dye (0.5%) and quantified by (A, B, and E-H) fluorescent imaging or (C and D) 
spectrophotometric analyses. (A, E, and F) Images (LI-COR Odyssey) and (B-D, G, and H) 
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MFI values are representative of two individual experiments (n = 3–6 per group). Ovalbumin 
(OVA; 10 mg/kg) and PBS were used as controls for systemic and local vascular leakage 
experiments, respectively.
(I) Levels of heparan sulfate detected in serum of mice (n = 3 per group) treated with 
ovalbumin (OVA), DENV2 NS1, WNV NS1, or YFV NS1 (all 10 mg/kg) as measured by 
ELISA. Untreated mice were used as a steady-state control.
For dextran-adapted dermal Miles assay, data were derived from three independent 
experiments and expressed as the fold-change ratio of the MFI obtained in each individual 
treatment group compared to PBS injection (dotted line in B). MFI was measured inside the 
leakage area by drawing a standard circular area in each treatment condition using ImageJ 
tools. Statistically significant differences between distinct treatment groups compared to the 
control groups were determined by a one-way ANOVA analysis using Dunnett’s test for 
multiple comparisons, with *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns 
(not significant), p > 0.05 . Error bars indicate SEM. Scale bars represent (A) 2.5 cm and (E 
and F) 0.5 cm.
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Figure 7. Model of Flavivirus NS1-Induced Endothelial Cell-Type-Dependent Hyperpermeability 
and Tissue-Specific Vascular Leakage and Its Potential Contribution to Flavivirus Pathogenesis 
and Disease
Flavivirus infections can affect specific tissues, including brain, lung, skin, liver, and the 
placenta during pregnancy, to cause neurotropic-encephalitic or systemic diseases in 
humans. Infection with any of the flaviviruses leads to secretion of NS1, a soluble viral 
protein that directly triggers endothelial hyperpermeability and vascular leakage associated 
with the disruption of key components of the endothelial glycocalyx layer, which lines the 
luminal surface of endothelial cells in the vasculature. The EGL is composed of 
monosaccharides such as sialic acid (Sia), glycosaminoglycans (GAGs) such as heparan 
sulfate, and heparan sulfate proteoglycans (HSPGs) such as syndecan-1. Here, we describe 
an endothelial cell-type-dependent increase in permeability and vascular leakage induced by 
different flavivirus NS1 proteins that reflect the disease pathogenesis of distinct flavivirus 
infections. DENV NS1 increases the permeability of endothelial cells from multiple tissues, 
such as lung, skin, umbilical vein, brain, and liver, consistent with the systemic disease 
caused by DENV. ZIKV NS1 induces endothelial dysfunction of umbilical vein and brain 
endothelial cells, reflecting severe congenital and neurological defects associated with Zika, 
while WNV and JEV NS1 only affect the barrier function of brain endothelial cells, in line 
with the neurotropic and encephalitic nature of WNV and JEV disease. Finally, YFV NS1 
increases the permeability of lung and especially liver endothelial cells, consistent with 
hepatic and systemic pathology of yellow fever virus. This selective permeability may 
contribute to the pathogenesis of the different flaviviruses by either inducing extravasation of 
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fluids that result in inflammation of tissues or facilitating virus dissemination into target 
organs that may lead to enhanced viral infection and disease.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-NS1 (7E11) in house conjugated to Alexa 568 Gift from R. Putnak 
(WRA) in-house 
conjugated
NA
Mouse monoclonal IgG anti-His Tag (AD1.1.10’)(AlexaFluor®647) NOVUS Biologicals Cat# NB100–64768AF647
Mouse monoclonal IgG anti-human CD138 (Syndecan-1) purified. Clone: 
DL-101
eBioscience Cat#14–1389–82; 
RRID:AB_467489
Rabbit polyclonal IgG anti-heparanase 1 (HPA1)(H-80) Santa Cruz Biotechnology Cat# sc-25825; 
RRID:AB_2120854
Mouse monoclonal IgG anti-human Cathepsin L Purified. Invitrogen Cat# BMS166; 
RRID:AB_10597594
Rabbit polyclonal IgG anti-neuraminidase 1 (Neu1)(H-300) Santa Cruz Biotechnology Cat# sc-32936; 
RRID:AB_2298197
Mouse monoclonal IgG anti-neuraminidase 1 (Neu1)(F-8) Santa Cruz Biotechnology Cat# sc-166824; 
RRID:AB_2149061
Goat polyclonal IgG anti-human ganglioside sialidase (Neu3)(N-18) Santa Cruz Biotechnology Cat# sc-55826; 
RRID:AB_2149075
Rabbit polyclonal IgG anti-human neuraminidase 2 (Neu2) Thermo Scientific 
(Invitrogen™)
Cat# PA5–35114; 
RRID:AB_2552424
Rabbit polyclonal IgG anti-human neuraminidase 3 (Neu3) Thermo Scientific 
(Invitrogen™)
Cat# PA5–45518; 
RRID:AB_2576484
Rabbit polyclonal IgG anti-human GAPDH (FL-335) Santa Cruz Biotechnology Cat# sc-25778; 
RRID:AB_10167668
Mouse IgM anti-heparan sulfate (F58–10E4) Amsbio Cat# 370255–1; 
RRID:AB_10891554
Mouse monoclonal IgG anti-6x His epitope Tag (HIS.H8) Thermo Scientific 
(Invitrogen™)
Cat# MA1–21315; 
RRID:AB_557403
Rabbit polyclonal anti-Alpha tubulin (loading control) Abcam Cat# Ab4074; 
RRID:AB_2288001
Rabbit polyclonal anti-Rab5 (early endosome marker) Abcam Cat# Ab18211; 
RRID:AB_470264
Goat anti-mouse IgG (AlexaFluor®647) Abcam Cat# ab150115; 
RRID:AB_2687948
Donkey anti-mouse IgG (AlexaFluor®647) Thermo Scientific 
(Invitrogen™)
Cat# A31571; 
RRID:AB_162542
Goat anti-rabbit IgG (AlexaFluor®568) Abcam Cat# ab175471; RRID: 
AB_2576207
Donkey anti-rabbit IgG (AlexaFluor®568) Abcam Cat# ab175470
Donkey anti-rabbit IgG (AlexaFluor®647) Abcam Cat# ab150075; RRID: 
AB_2752244
Donkey anti-goat IgG (AlexaFluor®568) Abcam Cat# ab175474; 
RRID:AB_2636995
Donkey anti-goat IgG (AlexaFluor®647) Abcam Cat# ab150131; 
RRID:AB_2732857
Donkey anti-mouse IgM (AlexaFluor®488) Jackson Immuno Research Cat# 715–545–140; 
RRID:AB_2340845
Goat anti-mouse IgG (AlexaFluor®680) Thermo Scientific 
(Invitrogen™)
Cat# A21057; 
RRID:AB_141436
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REAGENT or RESOURCE SOURCE IDENTIFIER
Goat anti-mouse IgG (AlexaFluor®750) Thermo Scientific 
(Invitrogen™)
Cat# A21037; 
RRID:AB_1500644
Donkey anti-mouse IgG (AlexaFluor®680) Abcam Cat# ab175774
Donkey anti-mouse IgG (AlexaFluor®750) Abcam Cat# ab175738
Goat anti-rabbit IgG (AlexaFluor®680) Thermo Scientific 
(Invitrogen™)
Cat# A21076; 
RRID:AB_141386
Goat anti-rabbit IgG (AlexaFluor®750) Thermo Scientific 
(Invitrogen™)
Cat# A21039; RRID: 
AB_1500687
Donkey anti-rabbit IgG (AlexaFluor®680) Abcam Cat# ab186692; 
RRID:AB_2725787
Donkey anti-rabbit IgG (AlexaFluor®750) Abcam Cat# ab175728
Donkey anti-human IgG (AlexaFluor®680) Jackson Immuno Research Cat# 709–625–149; 
RRID:AB_2340582
Goat anti-mouse IgG (AlexaFluor®488) Abcam Cat# Ab150117; 
RRID:AB_2688012
Chemicals, Peptides, and Recombinant Proteins
Gelatin solution, Type B, 2% in H2O, tissue culture grade Sigma Cat# G1393–20ML
Wheat germ agglutinin (AlexaFluor®647) Thermo Scientific 
(Invitrogen™)
Cat# W32466
Dextran, Alexa Fluor® 680; 10,000 MW, Anionic, Fixable, 5 m Life Technologies Cat# D34680
Formamide VWR Life science Cat# 0314
Fluorescein isothiocyanate (FITC)–dextran, average mol wt 70,000 Sigma Ca# FD70S-100MG
Recombinant dengue virus 2 NS1 (strain 16681) protein produced in 293 
human cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant Zika virus NS1 (Uganda MR766) protein produced in 293 
human cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant Zika virus NS1 (Suriname Z1106033) protein produced in 293 
human cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant West Nile virus NS1 (NY99) protein produced in 293 human 
cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant Japanese encephalitis virus NS1 (SA-14) protein produced in 
293 human cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant Yellow fever virus NS1 (17D) protein produced in 293 human 
cells. C-terminal 6x His-Tag
The Native Antigen 
Company
NA
Recombinant Dengue 2 Envelope (E) protein (DENV 2 E80%) produced in 
Sf21 cells.
In-house produced (gift 
from Aravinda M. de Silva)
NA
Recombinant DENV2/WNV Chimera (aa101–135WNV) produced in 293 
human cells. C-terminal 6x His-Tag
In-house produced (this 
paper)
NA
Human TNF-alpha Recombinant Protein Affymetrix/eBioscience Cat# 14–8329–63
Vascular endothelial growth factor (VEGF) Sigma Cat# V7259–10UG
Critical Commercial Assays and kits
MR-(FR)2 Magic Red® Cathepsin-L substrate Inmunochemistry Cat# 6138
Corning Transwell Multiple Well Plate with Permeable Polycarbonate 
Membrane Inserts
Fisher Scientific (Corning) Cat# 07–200–147
Corning® Transwell®-COL collagen-coated membrane inserts Sigma (Corning) Cat# CLS3495–24EA
Endpoint Chromogenic LAL QCL-1000 120 Test Kit Lonza Cat# 50–647U
EBMTM-2 Basal Medium Lonza Cat#: CC-3156
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REAGENT or RESOURCE SOURCE IDENTIFIER
EGMTM-2 MV Microvascular Endothelial SingleQuotsTM Kit Lonza Cat#: CC-4147
Endothelial Cell Medium ScienCell Cat#: 1001
Endothelial Cell Medium Cell Biologics Cat# 1166
Endothelial Cell Growth Medium 2 (Ready-to-use) PromoCell Cat# C-22011
FreeStyle serum free medium Thermo Scientific Cat# 12338018
Alexa Fluor 568 Antibody Labeling Kit Thermo Scientific 
(Invitrogen)
Cat# A20184
Experimental Models: Cell Lines
Human pulmonary microvascular endothelial cell line (HPMEC). Clone 
HPMEC.ST1–6R
Gift from J.C. Kirkpatrick, 
Johannes-Gutenberg 
University
NA
Human umbilical vein cord endothelial cells (HUVEC) Gift from Melisa Lodoen, 
UC Irvine (Manufacturer: 
Lonza)
Cat#:C2517A
Human dermal microvascular endothelial cell line (HMEC-1) Gift from Matthew Welch, 
UC Berkeley
NA
Human brain microvascular endothelial cells (HBMEC) Gift from Ana Rodriguez, 
NYU (Manufacturer: 
ScienCell)
Cat#: 1000
Human liver sinusoidal microvascular endothelial cells (HLSEC) Cell Biologics Cat# H-6017
Human 293F cells UC Berkeley Cell Culture 
facility
Custom order
Experimental Models: Organisms/Strains
Mouse: C57BL/6J The Jackson Laboratory Stock No: 000664
Oligonucleotides
Primer oligonucleotides for Mycoplasma screening sense GPO-3 
5′GGGAGCAAACAGGATTAGATACCCT3′
Eurofins scientific Custom order
Primer oligonucleotides for Mycoplasma screening antisense MGSO 
5′TGCACCATCTGTCACTCTGTTAACCTC3′
Eurofins scientific Custom order
Primer oligonucleotides for generating DENV/WNV Chimera 1r: CTC TTT 
CCC CAG GCC TTC CAG CCA ATT TCC AAT TTT TCC GTG GTG GCG 
GTG AGG CGT TTA GGT CCT GCC TGC ATG ATT CCT TTG ATG
Eurofins scientific Custom order
Primer oligonucleotides for generating DENV/WNV Chimera 2f: TGG AAG 
GCC TGG GGA AAG AGT ATT TTA TTT GCA CCA GAA CTC GCC 
AAC AAC ACC TTT GTG GTT GAT GGC CCC GAA ACA GCA GAA
Eurofins scientific Custom order
Recombinant DNA
pmab vector Gift from Michael 
Diamond (Washington 
University in St. Louis)
NA
Software and Algorithms
ImageJ (Image processing and analyses) NA https://www.nature.com/
articles/nmeth.2089
Image Studio Lite Ver 5.2 NA https://www.licor.com/bio/
products/software/
image_studio_lite/
Graph Pad Prism 6 2D scientific graphing and biostatistics) NA https://www.graphpad.com/
scientific-software/prism/
Adobe Illustrator CC 2018 Adobe Inc. http://www.adobe.com
Microsoft PowerPoint Microsoft Corporation https://www.microsoft.com/en-
us/
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REAGENT or RESOURCE SOURCE IDENTIFIER
FlowJo V10 FlowJo LLC https://www.flowjo.com/
Other
Zeiss LSM 710 Axio Observer Zeiss Axio Observer ZEISS CRL MIC, UC Berkeley
Chopstick Electrode Set for EVOM2 World Precision 
Instruments
STX3
EPITHELIAL VOLTOHMMETER 2 World Precision 
Instruments
EVOM2
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